Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA IV: FDA Stresses Burden Of Industry Meetings In User Fee Discussions

Executive Summary

FDA is emphasizing the difficulties of industry requested meetings in its early public discussion of the 2007 Prescription Drug User Fee Act reauthorization

You may also be interested in...



EOP2A Guidance Allows That Resource Constraints Might Block Meetings

FDA's final guidance on end-of-Phase 2A meetings codifies into policy the more realistic expectations of what the agency can handle in terms of meeting requests.

EOP2A Guidance Allows That Resource Constraints Might Block Meetings

FDA's final guidance on end-of-Phase 2A meetings codifies into policy the more realistic expectations of what the agency can handle in terms of meeting requests.

Fast Track Speeds Approval, Tufts Finds; Therapeutic Category Also Key

FDA’s fast track program may be the most successful of FDA’s user fee-era regulatory initiatives aimed at speeding new drug reviews, an analysis by the Tufts Center for the Study of Drug Development suggests.

Related Content

Topics

UsernamePublicRestriction

Register

PS046582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel